<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - CICLOSPORIN</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>CICLOSPORIN</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#handlingAndStorage" data-toggle="tab">Handling and storage</a></li>
          <li><a href="#preTreatmentScreening" data-toggle="tab">Pre-treatment screening</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Severe acute ulcerative colitis refractory to corticosteroid treatment</span>,
            </h4>
            <p class="specificity"><span class="route">By continuous intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                2 mg/kg, to be given over 24 hours, dose adjusted according to blood-ciclosporin concentration and response.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Severe active rheumatoid arthritis when conventional second-line therapy inappropriate or ineffective (administered on expert advice)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 2.5 mg/kg daily in 2 divided doses, then increased if necessary up to 4 mg/kg after 6 weeks, dose increase, if required should be gradual, discontinue if response insufficient after 3 months, dose adjusted according to response for maintenance and treatment reviewed after 6 months (continue only if benefits outweigh risks).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Short-term treatment of severe atopic dermatitis where conventional therapy ineffective or inappropriate (administered on expert advice)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 1.25 mg/kg twice daily (max. per dose 2.5 mg/kg twice daily) usually maximum 8 weeks but may be used for longer, if good initial response not achieved within 2 weeks, increase dose rapidly up to maximum.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Short-term treatment of very severe atopic dermatitis where conventional therapy ineffective or inappropriate (administered on expert advice)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 2.5 mg/kg twice daily usually maximum 8 weeks but may be used for longer.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Severe psoriasis where conventional therapy ineffective or inappropriate (administered on expert advice)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 1.25 mg/kg twice daily (max. per dose 2.5 mg/kg twice daily), increased gradually to maximum if no improvement within 1 month, initial dose of 2.5 mg/kg twice daily justified if condition requires rapid improvement; discontinue if inadequate response after 3 months at the optimum dose; max. duration of treatment usually 1 year unless other treatments cannot be used.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Organ transplantation (used alone)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                10&#8211;15 mg/kg, to be administered 4&#8211;12 hours before transplantation, followed by 10&#8211;15 mg/kg daily for 1&#8211;2 weeks postoperatively, then maintenance 2&#8211;6 mg/kg daily, reduce dose gradually to maintenance. Dose should be adjusted according to blood-ciclosporin concentration and renal function; dose is lower if given concomitantly with other immunosuppressant therapy (e.g corticosteroids); if necessary one-third corresponding oral dose can be given by intravenous infusion over 2&#8211;6hours.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Bone-marrow transplantation</span>,
                <span class="indication">Prevention and treatment of graft-versus-host disease</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                3&#8211;5 mg/kg daily, to be administered over 2&#8211;6 hours from day before transplantation to 2 weeks postoperatively, alternatively (by mouth) 12.5&#8211;15 mg/kg daily, then (by mouth) 12.5 mg/kg daily for 3-6 months and then tailed off (may take up to a year after transplantation).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Nephrotic syndrome</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                5 mg/kg daily in 2 divided doses, for maintenance reduce to lowest effective dose according to proteinuria and serum creatinine measurements; discontinue after 3 months if no improvement in glomerulonephritis or glomerulosclerosis (after 6 months in membranous glomerulonephritis).</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Ciclosporin is a calcineurin inhibitor.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Crosses placenta.</p><p>There is less experience of ciclosporin in pregnancy but it does not appear to be any more harmful than azathioprine. The use of ciclosporin during pregnancy needs to be supervised in specialist units.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <p>Dosage adjustment based on bilirubin and liver enzymes may be needed.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>In patients with nephrotic syndrome and renal impairment initially 2.5&#8239;mg/kg daily. Reduce dose by 25&#8211;50% if serum creatinine more than 30% above baseline on more than one measurement.</p>
            </section>
            <section class="doseAdjustments">
              <p>In rheumatoid arthritis, reduce dose if serum creatinine increases more than 30% above baseline in more than 1 measurement; if above 50%, reduce dose by 50% (even if within normal range) and discontinue if reduction not successful within 1 month.</p>
            </section>
            <section class="doseAdjustments">
              <p>In psoriasis and atopic dermatitis, reduce dose by 25&#8211;50% if serum creatinine increases more than 30% above baseline (even if within normal range) and discontinue if reduction not successful within 1 month.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Abnormal renal function (in non-transplant indications)</li>
            <li>malignancy (in non-transplant indications)</li>
            <li>uncontrolled hypertension (in non-transplant indications)</li>
            <li>uncontrolled infections (in non-transplant indications)</li>
            <li>use with tacrolimus specifically contraindicated</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain, anorexia, diarrhoea, fatigue, gingival hyperplasia, headache, hepatic dysfunction, hypercholesterolaemia, hyperkalaemia, hyperlipidaemia, hypertension, hypertrichosis, hyperuricaemia, hypomagnesaemia, muscle cramps, myalgia, nausea, paraesthesia, renal dysfunction (renal structural changes on long-term administration), tremor, vomiting,
              </p>
              <p>
                <strong>uncommon:</strong> Anaemia, oedema, signs of encephalopathy, thrombocytopenia, weight gain,
              </p>
              <p>
                <strong>rare:</strong> Gynaecomastia, haemolytic uraemic syndrome, hyperglycaemia, menstrual disturbances, micro-angiopathic haemolytic anaemia, motor polyneuropathy, muscle weakness, myopathy, pancreatitis, visual disturbances secondary to benign intracranial hypertension,
              </p>
        
          <h3>Specific side effects</h3>
              <p>
                <strong>notKnown:</strong> anaphylaxis,
              </p>
        
            <section class="advice">
                <h3>Visual disturbances</h3>
              <p>Discontinue if visual disturbances secondary to benign intracranial hypertension occur.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Mix solution with orange juice (or squash) or apple juice (to improve taste) or with water immediately before taking (and rinse with more to ensure total dose). Do not mix with grapefruit juice.</p><p>With capsules and oral solution, total daily dose should be taken in 2 divided doses.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>For <i>intravenous infusion</i> (<i>Sandimmun</i>
            <tm tmtype="reg"/>), give intermittently <i>or</i> continously <i>in</i> Glucose 5% <i>or</i> Sodium Chloride 0.9%; dilute to a concentration of 50&#8239;mg in 20&#8211;100&#8239;mL; give intermittent infusion over 2&#8211;6 hours; not to be used with PVC equipment.</p><p>Observe patient for signs of anaphylaxis for at least 30 minutes after starting infusion and at frequent intervals thereafter.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Patients and carers should be counselled on the administration of ciclosporin capsules and oral solution.</p>
            </section>
            <section class="generalPatientAdvice">
              <p>Avoid excessive exposure to UV light, including sunlight. In psoriasis and atopic dermatitis, avoid use of UVB or PUVA.</p>
            </section>
      </section>


      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
              <p>Patients should be stabilised on a particular brand of oral ciclosporin because switching between formulations without close monitoring may lead to clinically important changes in blood-ciclosporin concentration.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Hyperuricaemia
          </li>
          <li>
            in atopic dermatitis <i>Staphylococcus aureus</i> skin infections&#8212;not absolute contra-indication providing controlled (but avoid erythromycin unless no other alternative)
          </li>
          <li>
            in atopic dermatitis allow herpes simplex infections to clear before starting (if they occur during treatment withdraw if severe)
          </li>
          <li>
            in atopic dermatitis and psoriasis discontinue if lymphoproliferative disorder develops
          </li>
          <li>
            in psoriasis treat patients with malignant or pre-malignant conditions of skin only after appropriate treatment (and if no other option)
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Dermatological and physical examination, including blood pressure and renal function measurements required at least twice before starting treatment for psoriasis or atopic dermatitis.</p><p>Monitor liver function.</p><p>Monitor serum potassium especially in renal dysfunction (risk of hyperkalaemia).</p><p>Monitor serum magnesium.</p><p>Measure blood lipids before treatment and after the first month of treatment.</p><p>In psoriasis and atopic dermatitis monitor serum creatinine every 2 weeks for first 3 months then every month.</p><p>Investigate lymphadenopathy that persists despite improvement in atopic dermatitis.</p>
            </section>
            <section class="patientParameters">
              <p>Monitor kidney function&#8212;dose dependent increase in serum creatinine and urea during first few weeks may necessitate dose reduction in transplant patients (exclude rejection if kidney transplant) or discontinuation in non-transplant patients.</p>
            </section>
            <section class="patientParameters">
              <p>Monitor blood pressure&#8212;discontinue if hypertension develops that cannot be controlled by antihypertensives.</p>
            </section>
            <section class="patientParameters">
              <p>In long-term management of nephrotic syndrome, perform renal biopsies at yearly intervals.</p>
            </section>
            <section class="patientParameters">
              <p>In rheumatoid arthritis measure serum creatinine at least twice before treatment. During treatment, monitor serum creatinine every 2 weeks for first 3 months, then every month for a further 3 months, then every 4&#8211;8 weeks depending on the stability of the disease, concomitant medication, and concomitant diseases (or more frequently if dose increased or concomitant NSAIDs introduced or increased).</p><p>Monitor hepatic function if concomitant NSAIDs given.</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <p>Not licensed for use in severe acute ulcerative colitis refractory to corticosteroid treatment</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
                <h3>Brand name prescribing</h3>
              <p>Prescribing and dispensing of ciclosporin should be by brand name to avoid inadvertent switching. If it is necessary to switch a patient to a different brand of ciclosporin, the patient should be monitored closely for changes in blood-ciclosporin concentration, serum creatinine, blood pressure, and transplant function.</p>
            </section>
            <section class="prescribingAndDispensingInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>
            <i>Sandimmun</i>
            <tm tmtype="reg"/> capsules and oral solution are available direct from Novartis for patients who cannot be transferred to a different oral preparation.</p>
            </section>
      </section>


      <section class="tab-pane" id="handlingAndStorage">
        <h2>Advice regarding handling and storage</h2>

            <section class="handlingAndStorage">
              <p>Keep medicine measure away from other liquids (including water).</p>
            </section>
      </section>


      <section class="tab-pane" id="preTreatmentScreening">
        <h2>Pre-treatment screening</h2>

            <section class="preTreatmentScreening">
              <p>In psoriasis, exclude malignancies (including those of skin and cervix) before starting (biopsy any lesions not typical of psoriasis).</p>
            </section>
      </section>





      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of CICLOSPORIN</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            eye drops,
            eye ointment,

            <div id="PHP75375"><a href="../medicinalForm/PHP75375.html" data-target="#PHP75375" data-action="load">Capsule</a></div>
            <div id="PHP75523"><a href="../medicinalForm/PHP75523.html" data-target="#PHP75523" data-action="load">Oral solution</a></div>
            <div id="PHP75438"><a href="../medicinalForm/PHP75438.html" data-target="#PHP75438" data-action="load">Solution for infusion</a></div>
            <div id="PHP75598"><a href="../medicinalForm/PHP75598.html" data-target="#PHP75598" data-action="load">Eye drops</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
